The life sciences company, Avivagen is converting liability to equity and a grant of options. A total of $20,999.95 CDN in debt will be converted to common shares. The 291,666 common shares will be priced at $0.072 CDN each. The liability is due to board fees owed to Mr. Amin Khalifa.
1,200,000 options were granted to board members as part of a remuneration package. The options were priced at $0.09 CDN per share.
The conversion of debt to shares and option grants are both subject to approval of the TSX Venture Exchange.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol “VIV” and on OTC Pink as “CHEXF.” The Company’s goal is to develop and deliver scientifically-proven solutions that benefit companion and production animals by employing natural mechanisms for maintaining good health. Target markets include Livestock Productivity and Pet Wellness.
Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) – in Ottawa, Ontario and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.
No comments:
Post a Comment